Mirtazapina Ethypharm (Mirtazapine)

Mirtazapine acts as an antagonist at central presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also blocks postsynaptic 5‑HT2 and 5‑HT3 receptors and strongly antagonizes H1 histamine receptors, contributing to its antidepressant and sedative effects.

The appropriate dose of Mirtazapina Ethypharm is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made during treatment, and patients should follow the prescriber’s instructions without altering the regimen on their own.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike selective serotonin reuptake inhibitors, mirtazapine increases both norepinephrine and serotonin release and blocks certain serotonin receptors, which can lead to a different side‑effect profile, notably greater sedation and weight gain. It may be chosen when patients do not respond adequately to SSRIs or need additional sleep‑inducing effects.

Store the tablets at room temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

The medication is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include agranulocytosis or neutropenia, severe hypersensitivity reactions, and the emergence of suicidal thoughts or behaviors, particularly during the initial weeks of therapy. Patients should be monitored closely for any signs of infection, allergic reaction, or worsening mood.

Individuals with known hypersensitivity to mirtazapine or any of its excipients should avoid the drug. Caution is advised in patients with severe hepatic impairment, uncontrolled epilepsy, or those taking monoamine‑oxidase inhibitors; such situations require careful assessment by a healthcare professional.